ORGANIZATION

• Drug Pricing Rules Should Be Fundamentally Reviewed: JMA Chief
  November 28, 2016

• EFPIA, PhRMA “Regret” Out-of-Cycle Price Slash for Opdivo
  November 22, 2016

• EFPIA Japan Lauds MHLW Task Force’s Proposal on Blood Products and Vaccines Industries
  November 22, 2016

• JPMA to Straighten Up Industry Positions on FY2018 Pricing Reform
  November 18, 2016

• Opdivo Price Cut “Unavoidable” to Maintain Universal Healthcare: JMA Chief
  November 18, 2016

• FPMAJ, JPMA Issue Joint Statement on Emergency Price Cut for Opdivo
  November 17, 2016

• Drug Costs Is Main Culprit of Ballooning Medical Spending: Hodanren
  November 16, 2016

• Japan Society of Generic Medicines Calls for Lawmaker-Sponsored Bill to Push Biosimilar Use
  November 14, 2016

• PhRMA, EFPIA Members Conducted 825 Japan Clinical Trials in 2015
  November 8, 2016

• Japan Biosimilar Association Draws Gradual Rise in Membership, Mixed Interests
  November 7, 2016

• Realtor-Led Tokyo Life Sciences Hub Initiative Aims to Fill Void between Academia, Pharmas
  October 27, 2016

• Japan Should Adopt French-Type HTA: JMA Exec Suzuki
  October 26, 2016

• No Plan to Respond to MHLW Task Force’s Proposal on Vaccine, Blood Product Industries: JPMA
  October 21, 2016

• Keidanren Wades into Pricy Med Debate, Calls for Quick Price Review
  October 17, 2016

• Govt and Industry Should Generate Ideas Together: EFPIA Japan Chief
  October 7, 2016

• Value of Pharmaceutical Innovation Should Be Fully Recognized: PhRMA CEO
  September 30, 2016

• Generic Use Rate at 60.1% in April-June: JGA
  September 30, 2016

• Japan Wholesaler Chief Suzuki to Become IFPW Vice Chairman
  September 16, 2016

• Japan Needs Listing Rule Conditional on Possible Ad-Hoc Re-Pricing: Kono
  September 7, 2016

• Kenporen’s Kono Pushes for “Huge Seller” Re-Pricing for Opdivo before 2018
  September 7, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 45
• 46
• 47
• 48
• 49
• 50
• 51
• 52
• 53
• …
• Next ›
• 最終 »